drugset / Trial / NCT05726734
Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
RandomizedParallel-groupSingle-blindTreatment
Summary
Vonoprazan Amoxicillin and metronidazole based triple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the Vonoprazan, amoxicillin and metronidazole based triple therapy and the empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2025-02-06
- Completion
- 2026-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1 g | — |
| Subject | Bismuth Potassium Citrate | Unknown | 600 mg | — |
| Subject | Esomeprazole | Small molecule | 20 mg | — |
| Subject | Metronidazole | Small molecule | 0.4 g | — |
| Comparator | Vonoprazan | Other / unclassified | 20 mg | — |